RF
NAMS icon

Roxbury Financial’s NewAmsterdam Pharma NAMS Stock Holding History

Roxbury Financial’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-563
Closed -$19.1K – 438
2026
Q2 		$19.1K Hold
563
– – 0.02% 273
2026
Q1 		$18K Buy
563
+120
+27% +$3.91K 0.02% 269
2025
Q4 		$15.5K Buy
443
+119
+37% +$4.33K 0.01% 271
2025
Q3 		$9.21K Buy
324
+60
+23% +$1.44K 0.01% 293
2025
Q2 		$4.78K Buy
264
+195
+283% +$3.56K ﹤0.01% 310
2025
Q1 		$1.45K Buy
+69
New +$1.53K ﹤0.01% 330

Other funds holding NAMS

TSMHT
Thurston Springer Miller Herd & Titak Indianapolis, Indiana $61.1M AUM 22.51% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Roxbury Financial's NAMS Position: Q3 2026 in Review

Roxbury Financial sold out of NewAmsterdam Pharma (NAMS) in Q3 2026, closing a stake of 563 shares — an estimated $19.1K sold.

Roxbury Financial first reported a position in NAMS in Q1 2025 and held it in 6 quarters. The position peaked at $19.1K in Q2 2026. 4 funds tracked by Wall St. Rank hold NAMS as of Q3 2026.

  • Roxbury Financial reported no remaining NewAmsterdam Pharma position as of Q3 2026 after selling out during the quarter.
  • Roxbury Financial sold 563 NewAmsterdam Pharma shares in Q3 2026, an estimated $19.1K.
  • Roxbury Financial first reported a position in NewAmsterdam Pharma in Q1 2025 and held it in 6 quarters.
  • Roxbury Financial's NewAmsterdam Pharma position peaked at $19.1K in Q2 2026.
  • 4 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2026.

Based on Roxbury Financial's 13F filing for Q3 2026, filed 1 Oct 2026.